Overview

Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus

Status:
Terminated
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
This is a long-term safety study for Phase 2 subjects who choose to remain on Exubera® (inhaled insulin).
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Insulin
Insulin, Globin Zinc